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Abstract Objective: To compare the
effects of sodium bicarbonate and
lactate for continuous veno-venous
hemodiafiltration (CVVHDF) in
critically ill patients. Design and
settings: Prospective crossed-over
controlled trial in the surgical and
medical ICUs of a university hospital.
Patients: Eight patients with multi-
ple organ dysfunction syndrome
(MODS) requiring CVVHDF.
Intervention: Each patient received
the two buffers in a randomized se-
quence over two consecutive days.
Measurements and results: The fol-
lowing variables were determined:
acid-base parameters, lactate pro-
duction and utilization (13C lactate
infusion), glucose turnover (6,62H2-
glucose), gas exchange (indirect cal-
orimetry). No side effect was ob-
served during lactate administration.
Baseline arterial acid-base variables
were equal with the two buffers. Ar-
terial lactate (2.9 versus 1.5 mmol/l),
glycemia (+18%) and glucose turn-
over (+23%) were higher in the lac-
tate period. Bicarbonate and glucose
losses in CVVHDF were substantial,
but not lactate elimination. Infusing
13C lactate increased plasma lactate
levels equally with the two buffers.
Lactate clearance (7.8€0.8 vs 7.5€
0.8 ml/kg per min in the bicarbonate
and lactate periods) and endogenous
production rates (14.0€2.6 vs 13.6€
2.6 mmol/kg per min) were similar.
13C lactate was used as a metabolic
substrate, as shown by 13CO2 excre-
tion. Glycemia and metabolic rate
increased significantly and similarly
during the two periods during lactate
infusion. Conclusion: Lactate was
rapidly cleared from the blood of
critically ill patients without acute
liver failure requiring CVVHDF, be-
ing transformed into glucose or oxi-
dized. Lactate did not exert undesir-
able effects, except moderate hyper-
glycemia, and achieved comparable
effects on acid-base balance to bi-
carbonate.
Keywords Glucose turnover ·
Lactate oxidation · Strong ion
difference · Continuous renal
replacement therapy
Introduction
Continuous renal replacement therapy (CVVHDF) is
currently used in critically ill patients with acute renal
failure. Two buffers are usually used: sodium bicarbonate
and sodium lactate. Bicarbonate is often claimed to be a
better buffer in critically ill patients than lactate, since
bicarbonate exerts direct acid-base effects, while lactate is
dependent on tissue metabolism to exert its buffering
effect [1]. These metabolic processes may become altered
in patients with acute liver failure or refractory shock [2,
3]. Lactate may therefore accumulate and exert deleteri-
ous effects, but this is controversial [4]. In many other
patients, there is no clear advantage in using bicarbonate.
One argument suggests that lactate could even be a more
efficient buffer: bicarbonate may promote tissue acidosis,
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due to the rapid penetration of carbon dioxide into the
tissues, contrasting with the slow penetration of ions [5].
Another point to consider is related to the extracorporeal
elimination of buffers by renal replacement therapy,
which may also influence lactate and acid-base balances.
Thus, the advantages and disadvantages of these two
buffers remain to be established, particularly in patients
with hyperlactatemia. Based on our previous work on
lactate metabolism in severely ill patients [6, 7], we hy-
pothesized that lactate would be actively metabolized in
patients with multiple organ failure and hyperlactatemia
requiring CVVHDF.
This prospective study was designed to compare the
metabolic and acid-base effects of two different replace-
ment solutions, containing either sodium bicarbonate or
lactate, in critically ill patients requiring CVVHDF. The
end points were lactate and glucose metabolism, as well
as acid-base and electrolyte homeostasis.
Material and methods
Study population
The study was performed in the 17-bed surgical and 14-bed medical
intensive care units of our university hospital over a 9-month pe-
riod. With approval of the Institution Medical Ethics Review
Board, we enrolled eight critically ill adult subjects in this crossed-
over controlled trial with a randomized sequence. Written informed
consent was obtained from each patient or a relative.
Inclusion criteria were: age 16–75 years, acute renal failure
requiring CVVHDF with at least one additional organ failure.
Exclusion criteria were: blood lactate concentration more than
8 mmol/l; chronic renal failure requiring dialysis; moribund pa-
tients unlikely to survive more than 48 h; severe acute liver failure
(defined as cytolysis, or factor V <30%, and liver encephalopathy)
and active hemorrhage preventing accurate metabolic determina-
tions.
Monitoring and treatments
Systemic and pulmonary arterial blood pressures were monitored
(thermodilution catheter, Abott, North Chicago, IL, USA), cardiac
output was measured by thermodilution. SAPS II score (24 h after
admission) [8] and the daily SOFA score [9] were recorded.
Continuous veno-venous hemodiafiltration was performed with
a Prisma device (Gambro renal care products, Lakewood, CO,
USA). The filters (ANC 60) were changed before each 24 h pro-
tocol. Blood flow was set at 1.5–2.15 ml/kg per h, dialysis flow at
15 ml/kg per h and filtration at 5 ml/kg per h. Replacement fluid
was infused in the CVVHDF circuit as pre-dilution. The same fluid
solution (Lactasol or Hemosol BO, Hospital, Lyon, France, Ta-
ble 1) was used for dialysis and replacement. The ICU physician
ordered fluid balance, automatically regulated by the extra-renal
device. By design, the effluent fluid composition results from the
effect of both filtration and dialysis: therefore effluent fluid indi-
cates the net effect of these two processes.
Experimental protocol and measurements
Each patient received two different CVVHDF solutions containing
sodium bicarbonate or lactate in a randomized sequence over two
consecutive 24-h periods. The measurements (Fig. 1) were per-
formed during the last 6 h of each 24-h period. During the last 3 h
exogenous sodium lactate was infused to assess lactate pharmaco-
kinetics (lactate test) [10].
All fluid inputs and outputs were recorded, including residual
diuresis. Arterial and effluent fluid acid-base variables were mea-
sured hourly using a blood gas analyzer (Rapidlab Model 865 blood
gas analyser, Ciba-Corning Diagnostics, Switzerland). Hourly
substrate balances were calculated as the differences between the
inputs of all intravenous and enteral fluids and outputs determined
from CVVHDF effluents and residual diuresis.
Table 1 Composition of the hemofiltration replacement solutions
Concentration (mmol/l) Bicarbonate Lactate
Lactate 3 40
HCO3
– 32 0
Na+ 140 140
Ca++ 1.75 1.75
Mg++ 0.5 0.75
Cl– 109.5 105
K+ 0 0
Fig. 1 Diagram of the protocol performed in eight patients during
continuous veno-venous hemodiafiltration (CVVHDF) with lactate
and bicarbonate buffer in a sequential manner. G glucose sampling
for 6,62H2 glucose enrichment, X blood and CVVHDF effluent
sampling, and hemodynamic measurements
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In terms of a lactate test, lactate production and utilization were
determined using a pharmacokinetic model, based on the infusion
of an exogenous load of lactate [10], combined with an isotope
dilution method. A continuous infusion of 30 mmol/kg per min
sodium lactate, labeled with 13C lactate, was administered during
180 min. Breath samples were collected (hexatainers, Europa Sci-
entific Crew, UK) in quadruplicate 30 min immediately before
lactate infusion and every 30 min thereafter to determine 13CO2
excretion (as a reflection of lactate overall oxidation).
Glucose turnover was determined by means of an isotope di-
lution method. After the determination of basal glucose isotope
enrichment, a primed, continuous infusion of 6,62H2-glucose
(prime 6.7 mmol/kg per min, corrected for fasting plasma glucose,
continuous 0.33 mol/kg per min) was started. After 2.5 h, two
blood samples were collected at a 30-min interval for the calcula-
tion of glucose turnover. Resting oxygen consumption (V˙O2) and
CO2 production (V˙CO2) were measured during 60 min prior to and
during the last hour of lactate infusion, using a Deltatrac indirect
calorimeter (Datex Instruments, Helsinki, Finland) from ventilator
expiratory gases. Resting energy expenditure was calculated with
the equations of Livesey and Elia [11].
Analytical procedures (see detailed description in ESM)
Plasma 6,6 2H-glucose was measured with GC-MS on a Hewlett
Packard instrument (GC 5890-MS 5971, Hewlett Packard, Palo
Alto, CA). The strong ion difference was calculated using a sim-
plified Stewart’s equation: SIDapp=(Na
++K+)–(Cl–+lactate–) [12].
The concentrations of plasma insulin (kit from Biochem Im-
munosystems, Freiburg, Germany), cortisol (kit from Diagnostic
Products, Los Angeles, CA) and glucagon (kit from Linco Re-
search, St Charles, MO) were determined.
Calculations (see detailed equations in ESM)
The pharmacological clearance of lactate was calculated from the
lactate infusion rate and changes in plasma lactate levels, using the
standard pharmacokinetic calculation and taking into account
CVVHDF lactate elimination. Assuming that endogenous lactate
production was not altered by exogenous lactate [13], the former
was calculated as the product of basal lactate concentration and
lactate clearance during bicarbonate CVVHDF [10]. During lactate
CVVHDF, lactate administration by CVVHDF solutions was sub-
tracted. Lactate oxidation was determined from 13CO2 pulmonary
excretion. Glucose turnover was calculated with Steele’s equations
[14].
Statistical analysis
The results are expressed as means € SD. Comparisons between
groups and comparisons over time were carried out with two-way
ANOVA for the effect of treatment group and time. Post hoc
comparisons were made with Scheff and Dunett’s tests where
appropriate. Statistical analysis was performed using JMP Statis-
tical software (version 3.5.1, SAS Institute, Cary, NC). Probability
less than 0.05 was considered as statistically significant.
Results
The main characteristics of the patients are described in
Table 2. All were mechanically ventilated and suffered
from multiple organ failure (4–6 acute organ failures).
Five patients died during the ICU stay, one after transfer
to the ward and two were discharged alive from the
hospital. Predicted mortality according to SAPS II scores
was about 60%.
Continuous veno-venous hemodiafiltration with both
buffers was well tolerated by all patients: no side effect
related to extra-renal therapy was observed, except iso-
lated hyperlactatemia during lactate administration. Nei-
ther hemodynamic variables nor catecholamine adminis-
tration were different in the two treatment periods (Ta-
ble 3). CVVHDF settings as well as fluid balances were
similar over the two periods (Table 4).
Table 2 Patient characteristics
No. Age Sex Admission diagnosis BMI SAPS II SOFA No.
failures
LICU Main complications Outcome
1 77 F Abdominal aorta
surgery
28.3 52 11 6 10 Septic shock, hemorrhage Died
2 68 F Abdominal aorta
surgery
25.1 48 17 6 24 Ischemic colitis Pneumonia Alive
3 55 M Abdominal aorta
surgery
32.4 43 12 4 8 Paraplegia, ischemic
colorectitis
Alive
4 59 M Abdominal sepsis 28.3 31 8 4 18 Pneumonia, metabolic coma Alive
5 72 M Cardiac surgery 28.3 51 14 5 28 Mediastinitis, pneumonia,
septic shock
Died
6 61 F Endocarditis 24.8 77 19 6 8 Cardiac failure, hemiplegia,
septic shock
Died
7 67 M Myocardial infarct 32.0 76 17 5 21 Cardiac failure, hemorrhage Died
8 63 M Abdominal aorta
surgery
26.0 94 13 4 14 Septic shock, hemorrhage Died
BMI body mass index, SAPS simplified acute physiology score, SOFA sepsis-related organ failure score at initiation of the study, LICU
length of ICU stay, ARF acute renal failure, No. failures number of end organ failures including renal failure – maximum 6
Patient 4 died 1 month after leaving ICU
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Acid base and electrolytes
Arterial pH, PCO2 and bicarbonate were equal with the
two buffers (Table 3). This was also the case for the
SIDapp that was moderately reduced over the two periods
compared with normal values (44 meq/l) [12]. Albumin
concentrations were equally low during the two periods,
contributing to a normal pH despite reduced SIDapp (Ta-
ble 3).
Bicarbonate loss in the CVVHDF effluent was sub-
stantial, amounting to 800–1000 mmol/day in the two
groups. By contrast, lactate elimination was small,
amounting to 150 mmol/day (5.5€3.3% of the lactate
supplied) with lactate buffer and 70 mmol/day with bi-
carbonate (4.7€2.2%). Plasma electrolyte concentration
was not different during the two periods (Table 3).
Metabolic variables
Basal arterial lactate concentrations were significantly
higher in the lactate compared to the bicarbonate period
(mean values 3.3 versus 1.7 mmol/l, p<0.0001) (Table 3).
Baseline glycemia (+23%) and glucose turnover (+20%)
were significantly higher during the lactate period (Ta-
ble 5). Glucose loss in the CVVHDF amounted to about
60 g/day in the two periods (Table 3).
Compared with normal values, the baseline resting
metabolic rate was moderately increased with the two
buffers (Table 5). The mean baseline arterial pyruvate
concentration and lactate-pyruvate ratio were higher
during the lactate period (Table 3, p=0.009).
Both cortisol and glucagon plasma levels were high
over the study (Table 3) and did not differ between buf-
fers.
13C Lactate infusion test
Infusing 13C lactate increased equally the plasma lactate
levels in the two periods. Lactate clearance was similar
during the two periods: 7.8€0.8 versus 7.5€0.8 ml/kg per
min with bicarbonate and lactate, respectively. Endoge-
nous lactate production rates were also similar: 14.0€2.6
versus 13.6€2.6 mmol/kg per min in the bicarbonate and
lactate periods, respectively (Fig. 2, Table 5). 13C lactate
Table 3 Hemodynamic, acid-
base and chemistry values
Continuous veno-venous
hemodiafiltration
Lactate test
Bicarbonate Lactate Bicarbonate Lactate
Hemodynamics
Dobutamine (mg/min per kg) 4.9€3.5 4.8€3.8 4.8€4.4 4.8€4.2
Norepinephrine (ng/min per kg) 55€57 52€54 24€26 25€27
Cardiac index (l/min per m2) 2.4€1.1 2.6€1.1 3.0€1.5a 2.9€1.3a
Acid-base variables
pH blood 7.44€0.07 7.44€0.11 7.51€0.07a 7.49€0.11a
PCO2 blood (mmHg) 40.5€6.4 39.2€6.0 40.2€6.8 40.0€7.0
HCO3 blood (mmol/l) 26.6€3.6 25.8€4.8 31.1€4.3 29.6€5.3
Plasma chemistry
Na+ (mmol/l) 136€4 136€3 144€3a 144€2a
K+ (mmol/l) 4.1€0.3 4.1€0.3 3.8€0.4 3.8€0.4
Cl– (mmol/l) 105€2 106€3 106€2 106€3
Lactate (mmol/l) 1.7€0.3 3.3€1.2b 5.7€1.1a 7.7€2.4a
Pyruvate (mmol/l) 113€30 174€52b 274€78a 331€109a
Lactate/pyruvate blood 13.5€2.1 16.5€2.8b 20.1€5.7a 21.6€3.3a
Strong ion difference (meq/l) 33.3€2.7 31.5€3.6 37.1€2.6a 35.6€4.5a
Albumin (g/l) 17€3 18€3
Creatinine (mmol/l) 202€83 179€57
Glucose (mmol/l) 8.2€2.2 10.0€2.9b 9.1€2.6a 10.9€3.1a,b
Continuous veno-venous hemodiafiltration effluent
HCO3 (mmol/l) 28.6€4.2 24.1€3.8
b 32.3€4.2 27.6€4.3
Lactate (mmol/l) 1.8€0.3 7.6€2.0b 5.6€1.4a,b 12.1€3.8a,b
Glucose (mmol/l) 7.5€2.2 9.5€2.9b 8.6€2.4a 9.7€3.2a,b
a Different from baseline with the same buffer; bdifferent from bicarbonate buffer at the same time
point, p<0.05
Table 4 Main continuous veno-venous hemodiafiltration (CVVHDF)
parameters, means € SD, in ml/min·per kg
Bicarbonate Lactate
Blood flow rate 1.7€0.3 1.7€0.3
Dialysate flow rate 15.0€2.5 14.6€2.4
Hemofiltration flow rate 5.4€2.5 5.9€3.6
Effluent flow rate 21.5€3.7 21.7€4.4
Fluid balance 0.08€0.07 0.08€0.07
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was actively used as an energetic substrate, as shown by
the rapid appearance of 13CO2 in expired gas (Fig. 2).
During 13C lactate infusion, glycemia, pyruvate and
the lactate/pyruvate ratio significantly increased in the
two periods (Table 3). There were significant and simi-
lar increases in arterial pH, bicarbonate and SIDapp in
both groups (Table 3). Plasma Na+ increased markedly
(+8.5 mmol/l) while plasma Cl– did not change (Table 3).
The resting metabolic rate, oxygen consumption and
carbon dioxide production all increased significantly.
Cardiac index increased significantly and equally in the
two periods after lactate infusion.
Discussion
This study compared the effects of two CVVHDF solu-
tions, containing either lactate or bicarbonate, in patients
with multiple organ dysfunctions. The results show that
lactate administered with the CVVHDF solutions was
well tolerated, efficiently metabolized and exerted similar
acid-base effects to bicarbonate. Lactate increased glu-
cose turnover and glucose plasma level secondary to
stimulation of gluconeogenesis. The glucose loss in
CVVHDF was substantial.
Buffers for continuous veno-venous hemodiafiltration
The use of lactate and bicarbonate buffers remains con-
troversial, particularly the risks related with lactate ac-
cumulation in patients with metabolic failure. Sodium
lactate is cheap, stable and available in ready-for-use
solutions. Bicarbonate exerts direct buffering effects, but
bicarbonate-containing solutions must be prepared before
use, due to the instability of bicarbonate solutions. In
patients with severe tissue dysoxia or liver failure, lactic
acidosis is commonly observed and correlated with
mortality [15, 16]. This led to the assumption that exog-
enous lactate may be harmful and promoted the use of
Table 5 Metabolic values
Continuous veno-venous hemodiafiltration Lactate test
Bicarbonate Lactate Bicarbonate Lactate
Energy expenditure (kCal/24 h) 1684€425 1581€339 1884€397a 1790€295a
Respiratory quotient 0.87€0.11 0.86€0.11 0.83€0.12a 0.81€0.08a
VCO2 (ml/min) 210€54 195€44 230€47
a 210€42a
VO2 (ml/min) 244€64 229€54 281€60
a 260€53a
Glucose (mmol/l) 8.2€2.2 10.0€2.9b 9.1€2.6a 10.9€3.1a,b
Glucose turnover (mol/kg per min) 19.4€1.12 23.3€1.1b
Lactate clearance (ml/kg per min) 7.8€0.8 7.5€0.8
Endogenous production of lactate (mmol/kg per min) 14.0€2.6 13.6€2.6
Insulin (pmol/l) 29€18 62€54
Glucagon (ng/l) 711€509 597€341
Cortisol (nmol/l) 1675€1443 1801€1661
a different from baseline with the same buffer, bdifferent from bicarbonate buffer at the same time point, p<0.05.
VCO2 carbon dioxide excretion, VO2 oxygen consumption
Fig. 2 Lactate pharmacokinet-
ics and 13C lactate oxidation in
patients receiving continuous
renal replacement therapy with
either sodium bicarbonate or
lactate as buffer
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bicarbonate-buffered solutions [2, 17, 18, 19, 20, 21, 22].
A large exogenous lactate load should be avoided in pa-
tients with lactic acidosis for two reasons: first, the de-
creased ability of the body to use lactate and, second, the
better hemodynamic stability with bicarbonate [17, 20,
22, 23]. However, recent data show that exogenous lactate
is rapidly metabolized in patients with postoperative
cardiogenic shock or extensive liver resection [6, 7]. The
major problem in patients with hyperlactatemia is,
therefore, more related to the underlying medical condi-
tion than to the toxic effect of lactate per se. The inability
of dichloroacetate, a compound increasing pyruvate and
lactate utilization, to influence the clinical outcome in
critically ill patients with lactic acidosis, despite signifi-
cant reduction of lactate blood level, highlights this fact
[24].
Lactate and glucose metabolism
in continuous veno-venous hemodiafiltration
Lactate synthesis increases in conditions where glycolysis
is stimulated [25]. Plasma lactate increases when pyruvate
generation exceeds utilization or when pyruvate utiliza-
tion is altered by tissue dysoxia. In the latter condition,
anaerobic metabolism leads to the development of lactic
acidosis [26, 27], where acidosis is related to the hy-
drolysis of the ATPs generated during anaerobic glycol-
ysis and not to lactate metabolism per se.
After conversion into pyruvate, lactate has several
metabolic fates: mainly oxidation in the tricarboxylic
cycle, as well as transformation into glucose in the liver
and kidney. In these pathways, lactate utilization is as-
sociated with the consumption of protons, which is
equivalent to the generation of bicarbonate [28]. During
aerobic lactate metabolism there is no net acid production
and the acid-base balance remains in equilibrium [25].
Blood lactate is dependent on the balance between
lactate production and utilization. In the present study,
lactate infusion led to similar metabolic changes with
both buffers: increases in arterial lactate, pyruvate and
glucose concentrations, associated with a rise of arterial
pH and bicarbonate as well as increases in energy ex-
penditure. All these findings may be explained by active
lactate metabolism: transformation of lactate into pyru-
vate, an increase in glucose production in the gluconeo-
genesis process, generation of plasma bicarbonate con-
secutive to lactate metabolism, a rise in oxygen con-
sumption and metabolic rate related to the thermic effect
of lactate [25, 28]. The isotopic measurements, showing
the generation of 13CO2 following the infusion of
13C
lactate confirm the findings of the pharmacokinetic
model.
Lactate clearance rates observed in the present study
were moderately decreased in comparison with the values
that we previously reported in healthy subjects and in
surgical patients using similar methods [7]. This was little
influenced by the extracorporeal elimination of lactate by
CVVHDF, which was low, in accordance with previous
studies [29]. This low clearance rate may be related to the
poor clinical condition of the study population, charac-
terized by multiple organ failure and high ICU mortality.
The latter was very high (approximately 60%), as ex-
pected according to their medical condition [30]. Inter-
estingly, despite this altered lactate utilization, lactate
administered in CVVHDF fluids and lactate test was
rapidly metabolized, illustrating the large capacity of
tissues to use lactate.
Compared with normal values observed in healthy
subjects (approximately 10 mmol/kg per min), endoge-
nous production of lactate was increased in our patients,
like in postoperative surgical patients or cardiac surgery
patients with acute circulatory failure [6, 7]. Several
mechanisms may concur to increase lactate synthesis in
the body: (1) sympathoadrenal activation leads to stimu-
lation of the Na+/K+ ATPase and lactate synthesis [31]
was likely in our patients treated with catecholamines;
(2) proinflammatory cytokines [32]; (3) elevated glucose
turnover and cycling, both phenomena associated with
increased glycolysis and (4) lactate production by in-
flammatory cells, wounds and diseased organs [33].
To our knowledge, this is the first study comparing
lactate and glucose metabolism in patients receiving so-
dium lactate and bicarbonate for CVVHDF, using phar-
macokinetic and isotopic methods. Two studies were
previously performed in critically ill patients using a
similar approach. In the first, patients under CVVHDF
with bicarbonate buffer and normal lactatemia were
observed [29]. Total lactate clearance amounted to
15 ml/kg per min and lactate elimination by CVVHDF
was low, like in our study. Endogenous lactate production
amounted to 20 mmol/kg per min. In the second, septic
patients without renal failure were studied, with either
normal or elevated lactate levels [34]. Lactate clearances
were higher in the former than in the latter group, while
endogenous lactate production was similar in the two
groups. Although it seems difficult to compare lactate
metabolism in patients with such different clinical con-
ditions, increased lactate production was observed in all
these studies, while lactate clearance was maintained or
altered, according to organ and system failure.
Finally, higher glycemia and glucose turnover were
observed during lactate CVVHDF and lactate test, sug-
gesting that the auto-regulation of glucose endogenous
production was abolished. Indeed, glucose endogenous
production stays constant during the administration of
precursors of gluconeogenesis (like lactate) in healthy and
in critically ill subjects receiving TPN [35, 36]. This in-
dicates that the regulation of glucose metabolism was
altered in our patients.
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Sodium lactate versus bicarbonate as buffer
for continuous veno-venous hemodiafiltration
Several trials have compared sodium lactate and bicar-
bonate for CVVHDF [17, 20, 21, 22, 37]. Studies report
similar effects of lactate- and bicarbonate-buffered solu-
tions on acid-base balance [17, 20, 21, 37], while others
suggest that correction of acidosis may be delayed or less
efficacious with lactate [22]. This contrasts with the data
in patients with acute liver failure or hepatorenal syn-
drome, where lactate metabolism is altered in parallel to
its buffering capacity [3, 18]. In the present study, lactate
and bicarbonate exerted equivalent acid-base effects. The
price paid for lactate administration was a moderate in-
crease in lactate and glucose blood levels. Of note, acid-
base status was in the normal range in our patients; this
may have influenced lactate metabolism, which is known
to be depressed in severe acidosis [26]. The baseline
lactate/pyruvate ratio was not higher with lactate buffer
and increased in the two periods during 13C lactate infu-
sion. We have no clear explanation for this finding: it
might reflect a mass effect related to exogenous lactate
administration or disturbed intracellular redox state.
Our study provides new arguments to demonstrate that
lactate is a convenient substrate in most critically ill pa-
tients requiring CVVHDF. This may not be true in pa-
tients with severe liver failure or lactic acidosis, since the
experimental and human data clearly show the major
importance of liver function in lactate and acid-base
metabolism.
In conclusion, lactate administered as a buffer for
CVVHDF was rapidly metabolized in critically ill pa-
tients with multiple organ failure, without acute liver
failure. It was rapidly cleared from the blood, being
transformed into glucose or oxidized, as demonstrated by
combined pharmacokinetic and isotopic methods. Com-
parison with bicarbonate buffer showed that lactate did
not exert undesirable metabolic effects, except a moderate
rise of lactate and glucose blood levels. Lactate and bi-
carbonate buffers achieved comparable effects on acid-
base balance.
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